MediTrial s.r.o.
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At MediTrial s.r.o. the pulmonary department focuses on advancing treatments for severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD). Current studies aim to test new biologic and small‑molecule therapies that can lower the frequency of severe exacerbations and improve long‑term disease control.
- Severe eosinophilic asthma
- Chronic obstructive pulmonary disease (COPD)
- Evaluation of novel anti‑inflammatory agents
Recent trials are evaluating the efficacy of dexpramipexole in reducing asthma attacks and the long‑term safety of tozorakimab as an add‑on therapy for COPD patients who have stopped smoking.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Areteia Therapeutics Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Areteia Therapeutics Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MediTrial s.r.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO) | AstraZeneca AB | Phase III | Not Recruiting | Apr 2023 | May 2026 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Budesonide | 2 | Unknown | 2024-04-10 | 2024-04-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.